Search research articles
Contact Us
Filters
Showing results (251-260 of 275) with videos related to
Page
of 28
Sort By:
JCO Precision Oncology
|
December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Nitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
Blood
|
December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Judith E Karp, Karen Flatten, Eric J Feldman, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
JCO Clinical Cancer Informatics
|
August 15, 2024
Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy
Brittany A McKelvey, Elizabeth Garrett-Mayer, Donna R Rivera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Timothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Cell Metabolism
|
November 14, 2017
CD38-NAD<sup>+</sup>Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Shilpak Chatterjee, Anusara Daenthanasanmak, Paramita Chakraborty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Herbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2018
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas
Antonio Omuro, Kathryn Beal, Katharine McNeill, et al.
Clinical Pharmacology and Therapeutics
|
October 19, 2021
The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies
Donna R Rivera, Henry J Henk, Elizabeth Garrett-Mayer, et al.
Page
of 28
Search research articles
Search
Showing results (251-260 of 275) with videos related to
Sort By:
Page
of 28
JCO Precision Oncology
|
December 1, 2023
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With <i>ATM</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Nitin Rohatgi, Michael Rothe, Pam K Mangat, et al.
Blood
|
December 26, 2008
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
Judith E Karp, Karen Flatten, Eric J Feldman, et al.
JCO Precision Oncology
|
December 14, 2023
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study
Funda Meric-Bernstam, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 18, 2021
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
Sara M Tolaney, Elizabeth Garrett-Mayer, Julia White, et al.
JCO Clinical Cancer Informatics
|
August 15, 2024
Evaluation of Real-World Tumor Response Derived From Electronic Health Record Data Sources: A Feasibility Analysis in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy
Brittany A McKelvey, Elizabeth Garrett-Mayer, Donna R Rivera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Timothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Cell Metabolism
|
November 14, 2017
CD38-NAD<sup>+</sup>Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Shilpak Chatterjee, Anusara Daenthanasanmak, Paramita Chakraborty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Herbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2018
Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas
Antonio Omuro, Kathryn Beal, Katharine McNeill, et al.
Clinical Pharmacology and Therapeutics
|
October 19, 2021
The Friends of Cancer Research Real-World Data Collaboration Pilot 2.0: Methodological Recommendations from Oncology Case Studies
Donna R Rivera, Henry J Henk, Elizabeth Garrett-Mayer, et al.
Page
of 28